Online:
Visits:
Stories:
Profile image
By ETF Daily News (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

A Major Recovery Is Brewing In The Biotech & Healthcare Space

Friday, February 17, 2017 4:35
% of readers think this story is Fact. Add your two cents.

(Before It's News)

From Taki Tsaklanos: Biotechnology was once the darling of stock market investors. Not so anymore, since the summer of 2015 the sector collapsed from 400 points to 250 points in the IBB ETF.

Likewise, the health stock market sector lost its status of outperformer as the XLV ETF went from 75 points to 62 points. Note that biotech is part of the health sector (XLV).

Biotechnology is now showing the first signs of life. The IBB ETF is up 3 percent on the week.

We warned readers to watch closely the 250 level in this alert: Biotechnology and Health Sector Testing Long Time Support. Later on, we noticed that biotech refused to break down, and started to show a pattern of higher lows. Right now, the biotech stock market sector is testing a breakout level. Things will really get bullish once 300 points in the IBB ETF is cleared.

biotechnology stock market sector

The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) fell $1.78 (-0.61%) in premarket trading Friday. Year-to-date, IBB has gained 10.40%, versus a 5.01% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

The broader healthcare sector (XLV ETF) looks even more interesting. It recovered its losses, and is now ready to test all-time highs. Make no mistake, 75 points is a very important price level. A triple-test is significant as, mostly, three tests are sufficient for a breakout. However, a failure to breakout, after 3 tests, is bearish to say the least.

health care stock market sector

The Health Care SPDR ETF (NYSE:XLV) was unchanged in premarket trading Friday. Year-to-date, XLV has gained 6.70%, versus a 5.01% rise in the benchmark S&P 500 index during the same period.

XLV currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #1 of 36 ETFs in the Health & Biotech ETFs category.


This article is brought to you courtesy of Investing Haven.

You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (www.etfdailynews.com)



Source: http://etfdailynews.com/2017/02/17/a-major-recovery-is-brewing-in-the-biotech-healthcare-space/

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.